



IFW.

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Attorney Docket No.: 3430.02US01

Conklin

Confirmation No.: 9433

Application No.: 10/781,318

Examiner: Unknown

Filed: February 18, 2004

Group Art Unit: 1614

For: SSAO ENZYME SUBSTRATES FOR VASORELAXATION, AND METHODS OF
USE THEREOF

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date. No certification or fee is required.

Respectfully submitted,

Curtis B. Herbert, Ph.D., Esq.
Registration No. 45,443

Application No. 10/781,318

Customer No. 37137
Patterson, Thunte, Skaar & Christensen, P.A.
4800 IDS Center
80 South 8th Street
Minneapolis, Minnesota 55402-2100
Telephone: (612) 349-3008


Please grant any extension of time necessary for entry; charge any fee due to Deposit Account No. 16-0631.


CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

June 7, 2004

Date of Deposit


Curtis B. Herbert, Ph.D., Esq.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known

Application Number	3430.02US01
Filing Date	February 18, 2004
First Named Inventor	Conklin
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	3430.02US01

1 of 7

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ARCHER ET AL., The mechanism(s) of hypoxic pulmonary vasoconstriction: potassium channels, redox O2 sensors, and controversies. NIPS 17:131-137, 2002.	
		AWASTHI ET AL., Semicarbazide protection from in vivo oxidant injury of vascular tissue by allylamine. Toxicol Letters 66:157-163, 1993.	
		BABA ET AL. High-performance liquid chromatographic determination of serum aliphatic amines in chronic renal failure. Clinica Chimica Acta 136:48-56, 1984.	
		BARLOW ET AL., Hydrogen peroxide relaxes porcine coronary arteries by stimulating BKCa channel activity. Am J Physiol 275(44):H1283-H1289, 1998.	
		BOOMSMA ET AL., Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin. Clin Sci 88(6):675-679, 1995.	
		BOOMSMA ET AL., Circulating semicarbazide-sensitive amine oxidase is raised both in Type I (insulin-dependent), in Type II (non-insulin-dependent) diabetes mellitus and even in childhood Type I diabetes at first clinical diagnosis. Diabetologia 42:233-237, 1999.	
		BOOR ET AL., Allylamine cardiotoxicity: III. Protection by semicarbazide and in vivo derangements of monoamine oxidase. Toxicology 18:87-102, 1980.	
		BOOR ET AL., A role for a new vascular enzyme in the metabolism of xenobiotic amines. Circ Res 66:249-252, 1990.	
		BOOR ET AL., Methylamine metabolism to formaldehyde by vascular semicarbazide-sensitive amine oxidase. Toxicology 73:251-258, 1992.	
		CABLE ET AL., Endothelial regulation of vascular contraction in radial and internal mammary arteries. Ann Thorac Surg 67:1083-1090, 1999.	

EXAMINER
SIGNATUREDATE
CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known

Application Number	3430.02US01
Filing Date	February 18, 2004
First Named Inventor	Conklin
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	3430.02US01

Sheet

2

of

7

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		CASTILLO ET AL., Presence of SSAO in human and bovine meninges and microvessels. Neurobiol 7(3):263-272, 1999.	
		CONKLIN ET AL., Allylamine cardiovascular toxicity: evidence for aberrant vasoreactivity. Toxicol Appl Pharmacol 148:245-251, 1998.	
		CONKLIN ET AL., Amine metabolism: A novel path to coronary artery vasospasm. Toxicol Appl Pharmacol 175:149-159, 2001.	
		CONKLIN ET AL., Contribution of Serum and cellular semicarbazide-sensitive amine oxidase in amine metabolism and cardiovascular toxicity. Toxicol Sci 46:386-392, 1998.	
		CONKLIN ET AL., Vasoactive effects of methylamine in isolated human blood vessels: role of semicarbazide-sensitive amine oxidase, formaldehyde, and hydrogen peroxide. Am. J. Physiol Heart Circ Physiol 286:H667-H676, 2004.	
		CONKLIN ET AL., Poster Presentation at University of Wisconsin-Eau Claire Biology Department, 2001.	
		CONKLIN, D. J., Seminar at University of Wisconsin-Eau Claire Biology Department, April 2002.	
		CRACOWSKI ET AL., Functional comparison of the human isolated femoral artery, internal mammary artery, gastroepiploic artery, and saphenous vein. Can J Physiol Pharmacol 77:770-776, 1999.	
		DAR ET AL., The enzymatic systems involved in the mammalian metabolism of methylamine. Gen Pharmacol 16(6):557-560, 1985.	
		EKBLOM J. Potential therapeutic value of drugs inhibiting semicarbazide-sensitive amine oxidase: vascular cytoprotection in diabetes mellitus. Pharmacol Res 37(2):87-92, 1998.	
		ENRIQUE-TARANCON ET AL., Role of semicarbazide-sensitive amine oxidase on glucose transport and GLUT4 recruitment to the cell surface in adipose cells. J Biol Chem 273(14):8025-8032, 1998.	
EXAMINER SIGNATURE		DATE CONSIDERED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	3430.02US01
Filing Date	February 18, 2004
First Named Inventor	Conklin
Art Unit	1614
Examiner Name	Unknown

Sheet	3	of	7	Attorney Docket Number	3430.02US01
-------	---	----	---	------------------------	-------------

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		GÖKTÜRK ET AL., Studies on semicarbazide-sensitive amine oxidase in patients with diabetes mellitus and in transgenic mice. Biochim et Biophys Acta 1647:88-91, 2001.	
		GRONVALL ET AL., Autoradiographic imaging of formaldehyde adducts in mice: possible relevance for vascular damage in diabetes. Life Sci 63(9):759-768, 1998.	
		HAMILTON ET AL., Is hydrogen peroxide an EDHF in human radial arteries? Am J Physiol 280(6):H2451-H2455, 2001.	
		HAYES, B., Semicarbazide-sensitive amine oxidase activity in streptozotocin diabetic rats. Res Comm Chem Path Pharmacol 69(1):71-83, 1990.	
		HAYES ET AL., Benzylamine oxidase in normal and atherosclerotic human aortae. Exper Mol Path 38:243-254, 1983.	
		GUO-WEI, H., Arterial grafts for coronary artery bypass grafting: Biological characteristics, functional classification, and clinical choice. Ann Thorac Surg 67:277-284, 1999.	
		IESAKI ET AL., Inhibition of vasoactive amine induced contractions of vascular smooth muscle by hydrogen peroxide in rabbit aorta. Cardiovasc Res 28:963-968, 1994.	
		JAANKOLA ET AL., Human vascular adhesion protein-1 in smooth muscle cells. Am J Pathol 155:1953-1965, 1999.	
		KARASU C. Increased activity of H2O2 in aorta isolated from chronically streptozotocin-diabetic rats: effects of antioxidant enzymes and enzyme inhibitors. Free Rad Biol Med 27(1/2):16-27, 1999.	


EXAMINER
SIGNATURE

DATE
CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	3430.02US01
Filing Date	February 18, 2004
First Named Inventor	Conklin
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	3430.02US01

Sheet 4 of 7

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		KAPELLER-ADLER ET AL., Über das Vorkommen von Monomethylamin im Harn, Biochem Zeischrift 248:403-425, 1932.	
		KUMAR ET AL., Non-specific Cardiovascular Depressant Effect of Methyl Isocyanate (MIC) in Rats, J Toxicol Sci. 14:105-14. (1989).	
		LANGFORD ET AL., Developmental vasculotoxicity associated with inhibition of semicarbazide-sensitive amine oxidase. Toxicol Appl Pharmacol 155:237-244, 1999.	
		LANGFORD ET AL., Cultured vascular smooth muscle cells are resistant to methylamine toxicity: no correlation to semicarbazide-sensitive amine oxidase. Cardiovasc Toxicol 1:51-60, 2001.	
		LEBRUN ET AL., Dissociation by methylamine of insulin release from glucose-induced electrical activity in isolated mouse islets of Langerhans. Metabolism 34:1122-1127, 1985.	
		LEWINSOHN ET AL., A benzylamine oxidase distinct from monoamine oxidase B - Widespread distribution in man and rat. Biochem Pharmacol 27:1857-1863, 1978.	
		LYLES ET AL., The enhanced daily excretion of urinary methylamine in rats treated with semicarbazide or hydralazine may be related to the inhibition of semicarbazide-sensitive amine oxidase activities. J Pharm Pharmacol 41:97-100, 1989.	

EXAMINER
SIGNATUREDATE
CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	3430.02US01
Filing Date	February 18, 2004
First Named Inventor	Conklin
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	3430.02US01

Sheet

5

of

7


NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		LYLES G.A., Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidase: Biochemical, pharmacological and toxicological aspects. Int J Biochem Cell Biol 28(3):259-274, 1996.	
		MAFRA ET AL., Evaluation of biogenic amines in some Portuguese quality wines by HPLC fluorescence detection of OPA derivatives. Am J Enol Vitic 50(1):128-132, 1990.	
		MATOBA ET AL., Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Comm 290:909-913, 2002.	
		MESZAROS ET AL., Inhibitor sensitivity of human serum and vascular semicarbazide-sensitive amine oxidases. Neurobiology 8(2):215-223, 2000.	
		MITCHELL ET AL., Methylamine in human urine. Clin Chim Acta 312:107-114, 2001.	
		MOLDES ET AL., Molecular Cloning of a Major mRNA species in Murine 3T3 Adipocyte Lineage, J. Biol. Chem. 274:9515-9523 (1999).	
		PRECIOUS ET AL., Deamination of methylamine by semicarbazide-sensitive amine oxidase in human umbilical artery and rat aorta. Biochem Pharmacol 37(4):707-713, 1988.	
		RODRIGUEZ-MARTINEZ ET AL., Contractile responses elicited by hydrogen peroxide in aorta from normotensive and hypertensive rats. Endothelial modulation and mechanisms involved. Br J Pharmacol 125:1329-1335, 1998.	
EXAMINER SIGNATURE		DATE CONSIDERED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	3430.02US01
Filing Date	February 18, 2004
First Named Inventor	Conklin
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	3430.02US01

Sheet 6 of 7

NON PATENT LITERATURE DOCUMENTS


EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SALMI ET AL., A cell surface amine oxidase directly controls lymphocyte migration. Immunity 14:265-276, 2001.	
		TANI T. [Relaxation of vascular smooth muscle induced by formaldehyde (author's transl)]. Nippon Yakurigaku Zasshi 77(2):221-230, 1981.	
		THORNALLEY ET AL., Negative association between erythrocyte reduced glutathione concentration and diabetic complications. Clin Sci 91:575-582, 1996.	
		VIDRIO ET AL., Semicarbazide-sensitive Amine Oxidase Substrates Potentiate Hydralazine Hypotension: Possible Role of Hydrogen Peroxide, Journal of Pharmacology and Experimental Therapeutics, 307:497-504, 2003.	
		WIBO ET AL., Subcellular location of semicarbazide-sensitive amine oxidase in rat aorta. Eur J Biochem 112:87-94, 1980.	
		WINGENDER W., High-performance liquid chromatographic method for the quantitative analysis of a synthetic copolymer with antitumor activity (copovithane) and methylamine in human plasma and urine. Jrl Chromot 273:319-326, 1983.	
		YANG ET AL., Emergency treatment and care of 35 patients with monomethylamine poisoning. [in Chinese, English abstract]. Chung-Hua Hu Li Tsa Chih Chinese J Nurs 30(2):83-85, 1995.	

EXAMINER
SIGNATUREDATE
CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	3430.02US01
Filing Date	February 18, 2004
First Named Inventor	Conklin
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	3430.02US01

Sheet 7 of 7

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		YU P., Oxidative deamination of aliphatic amines by rat aorta semicarbazide-sensitive amine oxidase. J Pharm Pharmacol 42:882-884, 1990.	
		YU ET AL., Impairment of methylamine clearance in uremic patients and its nephropathological implications. Clin Nephro 49(5):299-302, 1998.	
		YU ET AL., Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia 40:1243-1250, 1997.	
		YU ET AL., Formaldehyde produced endogenously via deamination of methylamine. A potential risk factor for initiation of endothelial injury, Atherosclerosis 120 (1996) 189-197.	
		YU ET AL., Oxidative deamination of methylamine by semicarbazide-sensitive amine oxidase leads to cytotoxic damage in endothelial cells. Possible consequences for diabetes. Diabetes 42:594-603, 1993.	
		YU ET AL., Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim Biophys Acta 1647:193-199, 2003.	
		YU PH, Increase of formation of methylamine and formaldehyde in vivo after administration of nicotine and the potential cytotoxicity. Neurochem Res 23(9):1205-1210, 1998.	
		YU ET AL., Formation of Formaldehyde from Adrenaline In Vivo: a Potent Risk Factor for Stress-Related Angiopathy, Neurochemical Res 22(5): 615-620, 1997.	

EXAMINER
SIGNATUREDATE
CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.